Iomeron (Iomeprol)

Iomeprol is a non‑ionic, low‑osmolar iodine‑based compound that distributes in the extracellular fluid after injection. The iodine atoms strongly absorb X‑ray photons, increasing attenuation of the blood and surrounding tissues. This creates a temporary contrast between vascular structures and adjacent organs, producing enhanced images on X‑ray, CT or fluoroscopic systems.

The dose of Iomeron is individualized by the prescribing physician based on the type of imaging study, patient size, renal function and the required level of vascular opacification. Dosage is calculated in millilitres of the injectable solution and administered by a qualified healthcare professional under controlled conditions.

The safety of Iomeron in pregnancy and lactation has not been definitively established. Iodinated contrast agents cross the placenta and may be excreted in breast milk, so use is generally avoided unless the diagnostic benefit outweighs potential risks. Clinicians should assess each case carefully and discuss alternatives when possible.

To place an order, submit an enquiry on the Iomeron product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and assistance with import documentation.

Iomeron is a low‑osmolar, non‑ionic iodine contrast medium, which generally offers a lower incidence of discomfort and adverse reactions compared with older high‑osmolar agents. Compared with other low‑osmolar products, its physicochemical profile provides comparable image quality while maintaining a favorable safety margin, especially in patients with moderate renal impairment.

Iomeron should be stored at controlled room temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze or shake the vial; inspect for particulate matter before use and discard any product that appears discolored or contaminated.

Iomeron is supplied as an injectable solution for intra‑arterial, intravenous or intrathecal administration. The preparation is drawn into a sterile syringe or infusion set and delivered by a qualified clinician using standard aseptic techniques. The rate and volume are adjusted according to the imaging protocol and patient characteristics to achieve optimal contrast enhancement.

The most serious risks include severe allergic reactions such as anaphylaxis, acute renal impairment especially in patients with pre‑existing kidney disease, and cardiovascular events like arrhythmias or hypotension. Prompt recognition and emergency management are essential; patients should be monitored closely during and after administration.

Iomeron is contraindicated in patients with a known hypersensitivity to iodine‑based contrast media, a history of severe anaphylactic reactions to similar agents, or uncontrolled hyperthyroidism. Caution is also advised for individuals with compromised renal function, severe cardiac disease, or those who are pregnant unless the diagnostic benefit justifies the potential risk.